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ABSTRACT 
 
Plasma Concentration of Glucosamine and Chondroitin  
Sulfate in Horses Following an Oral Dose. (December 2004) 
Courtney Ann Welch, B.S., Texas A&M University 
Co-Chairs of Advisory Committee: Dr. Gary D. Potter 
                      Dr. Pete Gibbs 
 
 
 This study was conducted to study absorption of glucosamine and chondroitin 
sulfate and to measure any changes in blood concentration of these compounds following 
feeding them to horses in different amounts.  Six mature mares were used in a replicated 
3x3 Latin square designed experiment.  The experiment consisted of three 15-day 
periods, which included 10 days of diet adaptation followed by a 5-day sampling period.  
Blood was drawn on one day during each sampling period.  Horses were fed a control 
diet (40% hay, 60% concentrate) balanced to meet NRC (1989) requirements for 
maintenance of mature horses.  In one experimental diet, 2.0 g chondroitin sulfate and 5.5 
g glucosamine were added to the basal ration at each feeding.  In the other experimental 
diet, 3.5 g chondroitin sulfate and 8.5 g glucosamine were added to the basal ration at 
each feeding.  Following total collections, blood was centrifuged and plasma was 
harvested and data analyzed for the presence of each compound.  Analyses for plasma 
glucosamine were performed in the Protein and Chemistry Lab at Texas A&M University 
using HPLC.  Chondroitin sulfate in the plasma was analyzed using a color reagent, 
dimethylmethylene blue, followed by UV spectrophotometry.   
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 There were no significant differences (P<0.05) in the concentration of chondroitin 
sulfate or glucosamine concentrations in plasma when comparing the three different diets.  
This leads to a conclusion that these compounds were not absorbed through the intestinal 
wall into the bloodstream in the same form as they were fed. This poses a question as to 
whether or not oral forms of these compounds are absorbed and are able to migrate to 
joints through the blood to improve joint function.  With the significant economic impact 
that products containing chondroitin sulfate and glucosamine are making in the animal 
nutrition industry, more research is needed to further elucidate actual efficacy of these 
compounds in diet supplements for horses. 
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CHAPTER I 
INTRODUCTION 
 
Numerous dietary supplements containing glucosamine and/or chondroitin sulfate 
are currently being marketed as a way to help support, improve or restore the health of 
horses’ joints (Ramey et al., 2002).  Glucosamine and chondroitin sulfate are fairly new 
products to the horse industry, and currently studies of the efficacy of these products in 
equine joint disease have produced mixed results (White et al., 2003). Most of the 
research done thus far has been performed on more typical lab animals such as dogs and 
rats.  There is little if any accurate data on the absorption of orally dosed chondroitin 
sulfate and glucosamine in the equine.   
Understanding how glucosamine and chondroitin sulfate work as 
chondroprotective agents ultimately could translate into improved prevention or 
management of cartilage degeneration in athletic and performance horses (Orth et al., 
2002).  A well-performed study on the absorption of glucosamine and chondroitin sulfate 
from the gastrointestinal tract of the equine is needed to provide a base for future research 
on the efficacy of these products in the equine industry. 
 
 
 
 
______________ 
This thesis follows the style and format of the Journal of Animal Science. 
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CHAPTER II 
REVIEW OF LITERATURE 
 
Degenerative joint disease and its associated joint pathology contribute 
significantly to musculoskeletal lameness and loss of function in performance and 
pleasure horses (Hanson, 1996).  Numerous dietary supplements containing glucosamine 
and/or chondroitin sulfate are marketed as a way to help support, improve or restore the 
health of horse’s joints (Ramey et al., 2002). The main goal of the medical therapy in 
treatment of degenerative joint disease is to restore and maintain normal joint function by 
alleviating pain, decreasing joint inflammation, and protecting the cartilage from further 
injury (Anderson et al., 1999). Recent research in the medical management of these joint 
problems has focused on slowing the process of cartilage degradation and promotion of 
cartilage matrix synthesis (Hanson, 1996). Glucosamine and chondroitin sulfate are 
macromolecules endogenous to cartilage and have been used in veterinary medicine for 
several years with mixed results.  Benefits of oral supplements containing glucosamine 
and chondroitin sulfate have been shown in many different types of animal models and 
some human clinical studies (McLaughlin, 2000).  Studies of the efficacy of these 
products in equine joint disease have produce mixed results (White et al., 2003).  
Elucidating their modes of action at the cellular level is becoming an important area of 
study in arthritis research (Orth et al., 2002).  Understanding how glucosamine and 
chondroitin sulfate work as chondroprotective agents ultimately could translate into 
improved prevention or management of cartilage degeneration in athletic and 
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performance horses (Orth et al., 2002).  The first step in this line of research is to 
determine the absorption of oral products from the gastrointestinal tract in the equine.   
The reported combination of glucosamine and chondroitin sulfate has been used 
in veterinary medicine for several years in the USA to treat degenerative joint disease in 
small (Moore, 1996) and large (Hanson et al., 1997) animals with some favorable clinical 
results and no reported clinical side effects in healthy dogs.  A survey of veterinary 
practices revealed that intra-articular lesions account for 33% of all diagnosed equine 
conditions.  Traditional treatments, including surgery, nonsteroidal anti-inflammatory 
drugs and corticosteroids, have been augmented by additional medications possessing the 
potential to slow the progression of the disease in addition to treating its symptoms 
(Fenton et al., 2002).  Among these new methods of disease prevention are a class of 
orally administered “nutraceuticals”, the most common of which contain glucosamine 
and/or chondroitin sulfate (Fenton et al., 2002).  Since chondroitin sulfate and 
glucosamine are considered nutritional supplements, they are not subject to the same 
stringent requirements for quality as are pharmaceutical products (Ramey et al., 2002). 
Currently there is a lack of experimental evidence proving the efficacy of these products 
on joint health when given orally.  Without good, controlled clinical trials, practitioners 
have had to rely on sporadic anecdotal information coupled with their professional 
judgment on the worthiness of many “nutraceutical” agents available in the market to 
treat degenerative joint disease in animals (Anderson et al., 1999).  
 A mail survey was sent to 3080 small-animal practitioners on the perceived 
clinical efficacy and safety of oral “nutraceuticals” such as chondroitin sulfate and 
glucosamine.  Sixty four percent of the practitioners reported that they were 
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recommending the oral nutraceutical to their clients (Anderson et al., 1999).   Most 
practitioners (83%) believed response to treatment with the studied product occurred 
within four weeks and they rated the clinical efficacy to be either ‘good’ or ‘excellent’ in 
improving mobility, alleviating pain and improving attitude in the majority of treated 
animals (Anderson et al., 1999).  With the rate of distribution and the highly perceived 
clinical efficacy, the potential importance of these products is great and warrants much 
scientific research to be conducted. 
 Glucosamine and chondroitin sulfate are macromolecules endogenous to 
cartilage.  Articular cartilage is composed of chondrocytes, which synthesize and deposit 
around themselves a watery matrix.  This matrix gives cartilage its resiliency and tensile 
strength and is composed of collagen and proteoglycans (Hanson, 1996).  
Glycosaminoglycans are highly negatively charged long chains of repeating 
disaccharides that attach to a core protein (MacLeod, 2001). Glycosaminoglycans (GAG) 
aggregate with hyaluronic acid to form proteoglycan macromolecules (Davidson, 2000).   
Healthy chondrocytes can replenish up to a 50% loss in matrix volume (Davis, 1998).   
Any insult to cartilage can cause a loss of GAG content and therefore a loss of elasticity 
and ability to bear and transmit forces efficiently, resulting in a cascading cycle of more 
cartilage insults. Chronic overuse can increase the rate of cartilage breakdown and exceed 
the chondrocytes’ ability to replace the matrix (MacLeod, 2001).  Conditions such as this 
result in a need to supply the raw materials (nutrients) to the cartilage, so that the 
synthesis process is not impaired and cartilage may replenish itself  (Hanson, 1996). 
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Chondroitin Sulfate 
 Chondroitin sulfate (CS), the most abundant GAG in the body, is a long chain 
polymer of a repeating disaccharide unit galactosamine sulfate and glucuronic acid 
(Hanson et al. 1997).  Glycosaminoglycans are present in various mammalian organs and 
tissues such as cartilage, blood vessels, cell surfaces and intracellular organelles and are 
also normally found in plasma. The mass of CS is variable ranging from 14,000 Da to 
30,000 Da. The major site of metabolism for circulating chondroitin sulfate is the liver, 
where the GAG, depending on the animal species, may be partly degraded to 
oligosaccharides that subsequently lose their sulfate groups as inorganic sulfate (Baici et 
al., 1992).  Inorganic sulfate and intact polymeric chondroitin sulfate are excreted in the 
urine (Wood et al., 1973).  Parts of the glycosaminoglycans are taken up by the cells, 
where they are degraded to low molecular mass products (Revell and Muir, 1972).   
The bioavailability of oral chondroitin sulfate in animals is a subject debated in 
the literature.  Palmieri et al. (1990) found more than 70% absorption when using ³H-
labeled CS fed to rats and dogs.  Andermann and Dietz (1982) investigated the absorption 
of chondroitin sulfate in rabbits after oral administration and found neither absorption nor 
release of a characteristic-clearing factor into the blood stream. One factor that may affect 
the absorption of CS is the chain length of the molecule.  Current theory supports higher 
permeability for CS with lower molecular weight (Eddington and White, 2001).  The 
mammalian intestinal epithelium is a highly effective barrier, which hinders the diffusion 
of a wide variety of compounds, especially those that are charged and/or have a high 
molecular mass (Baici et al., 1992).  The most important factor determining the intestinal 
absorption of an organic electrolyte is its degree of ionization (Schanker et al., 1958). 
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Oral intake of chondroitin sulfate implies exposure to both the enzymes of the stomach 
and of the intestine (Baici et al., 1992).  Considering all the above-mentioned 
experimental evidence, it is of great importance that absorption of chondroitin sulfate is 
studied in the equine.   
 Absorption of chondroitin sulfate has been reported in studies in which 
radiolabeled compounds were used. Pinocytosis is the main mechanism of GI absorption 
of GAG’s (Conte et al., 1995).  Palmieri et al. (1990) demonstrated that more than 70% 
of the radioactivity administered orally to rats and dogs has absorbed.  The labeling 
methods used by the authors suggest that each chondroitin sulfate molecule bear a single 
label at the reducing end of the molecule (Baici et al., 1992).  The in vivo enzymatic 
degradation of the polymer proceeds, step by step from the non-reducing end toward the 
reducing end (Conte et al., 1995).  This sort of labeling is not representative of the whole 
molecule. Conte et al. (1991) reported on the plasma concentration of chondroitin sulfate 
given orally to man and concluded that the absolute bioavailability of the 
glycosaminoglycan was 13.2% of the administered dose.  Judging from the amplitude of 
the standard deviation reported for total chondroitin sulfate, it must be concluded that the 
authors also observed large variations, at least among different volunteers (Baici et al., 
1992).  Conte et al. (1995) reported that when feeding ³H-chondroitin sulfate to rats and 
dogs, more than 70% of radioactivity was absorbed.  They found low molecular mass CS 
in synovial fluid of these animals, but to date there are no enzymes currently known to 
catalyze reoxidation of the monosaccharides of GAG chains (Conte et al., 1995).  The 
experimenters also found high molecular mass CS, higher than what was fed.  This may 
be due to the binding of the polysaccharide and its derivatives with proteins (Conte et al., 
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1995).  In a study of absorption of sulfated glycopeptides (GLPS), it was reported that 
when rats and dogs were fed a ³³S GLPS almost all of the radioactivity resulting from a 
single oral dose was excreted in the feces with in five days (Chasseaud, 1972).  More 
specifically, 88.3% of the 89.3% recovered GLPS was found in the feces of rats within 
five days, and 96.0% of the 97.0% recovered GLPS was found in the feces of dogs within 
five days.  Oral dosing of GLPS in humans was also studied and it was reported that most 
of the radioactivity was rapidly eliminated in four days (Chasseaud, 1972). 
Glucosamine 
Glucosamine (GlucN), an amino sugar synthesized by chondrocytes from glucose 
and glutamine, is an important intermediate for the formation of numerous compounds 
including GAGs (Davidson, 2000). Glucosamine is a small molecule (m.w. = 179.17) and 
very soluble in water.  The pKa of GlucN is very favorable for absorption from the small 
intestine and in general for the crossing of biological barriers in the body (Setnikar et al., 
1986). As a result of their structure, GAGs bind large amounts of water, thereby allowing 
them to function in support of the cellular and fibrous components of tissue (Johnston, 
1997).  Certain articular disorders are due to a “degenerative” process affecting the 
cartilage.  The causes of this process are unknown, but an important factor is represented 
by a defect of the biosynthesis and the turnover of glucosamine and of other aminosugars 
(Setnikar et al., 1986). Studies have shown that administration of GlucN tends to 
normalize cartilage metabolism and stimulate the synthesis of proteoglycans so that 
articular function is partially restored (Hanson, 1996).  
 Glucosamine has been widely studied as an agent to reduce or alleviate symptoms 
of arthritis.  Glucosamine at concentrations as low as 0.5 mg/ml has been shown to 
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inhibit nitric oxide production (Orth et al., 2002).  Patients with arthritis have higher 
concentrations of nitric oxide catabolites in their serum and urine than age-matched 
individuals with no clinical signs of arthritis (Grabowski et al., 1996).  Articular cartilage 
explants from horses with moderate osteoarthritis produce more nitric oxide than normal 
cartilage (Orth et al., 2002).  Glucosamine was also found to inhibit PGE2 production.  
Prostaglandin E2 is upregulated during an inflammatory response and is found in 
increased concentrations in the synovial fluid of patients with arthritis (Orth et al., 2002).  
Horses with degenerative joint diseases have elevated concentrations of PGE2 (May et al., 
1994). Therefore, the ability of glucosamine to alleviate clinical signs of osteoarthritis 
could be due to its ability to inhibit PGE2 synthesis (Orth et al., 2002).   
 Glucosamine absorption from the gastrointestinal tract has been studied on many 
occasions in many animals.  In a study of intestinal absorption of GlucN in rats, it was 
reported that GlucN is easily absorbed through a simple carrier mediated transport across 
the intestinal wall.  GlucN was found to be absorbed without modification to its 
molecular structure (Tesoriere, 1972).  Glucosamine has also been found to concentrate 
in certain organs and tissues such as the liver, kidney and cartilage.  The liver is the main 
organ responsible for the metabolism and biotransformation of exogenous GlucN 
(Setnikar et al., 1984).  The kidney concentrates GlucN and excretes it in the urine 
(Setnikar et al., 1986).  In a study using uniformly labeled GlucN, it was found that 
GlucN is rapidly and well absorbed from the GI tract of dogs.  It was reported that the 
absorption in dogs was 87% of the administered dose (Setnikar et al., 1986).  In another 
study using labeled GlucN fed to rats, it was reported that the radioactivity found was not 
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due to GlucN, but was from chemical entities which changed over time (Setnikar et al., 
1984). 
 A synergistic rather than an additive effect would be expected by combining 
glucosamine and chondroitin sulfate, since both agents are endogenous to chondrocytes 
(Hanson et al., 1997).  The combination of the two was studied and was found able to 
decrease proteoglycan degradation (Orth et al., 2002).  With increased popularity of CS, 
glucosamine and other “nutraceuticals” for treatment of joint problems, bioavailability of 
these compounds becomes even more important.  A better understanding of the 
bioavailability of these products can alleviate confusion in the horse industry and provide 
much needed data on a new and exciting subject.   
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CHAPTER III 
MATERIALS AND METHODS 
 
Management of Animals 
Six mature mares were used in a replicated 3x3 Latin square designed experiment.  
Their ages and weights ranged from 3-10 years and 472-557 kg, respectively.  The horses 
were maintained at the Texas A&M University Horse Center following a protocol 
approved by the Institutional Agricultural Animal Care and Use Committee.  Prior to the 
experiment, the horses were dewormed, vaccinated and their teeth were floated where 
necessary.   
Experimental Diets 
 For each period of the Latin square, the horses were randomly assigned to one of 
three treatment groups, with two horses per group.  The control diet (diet1) was fed at 
1.5% of body weight and was balanced to meet or exceed NRC (1989) requirements for 
maintenance of mature horses.  It contained a ratio of 40% bermudagrass hay and 60% 
concentratea.  When the horses were on the level one experimental diet (diet 2) they were 
administered a dose of 2.0g chondroitin sulfate and 5.5g glucosamine, top dressed on the 
control diet, at 7:00am and 7:00pm.  When the horses were on the level two diet (diet 3) 
they received 3.5g chondroitin sulfate and 8.5g glucosamine fed at the same time and in 
the same manner as above. Chondroitin sulfate and glucosamine dosages were 
determined by review previous literature using these compounds fed in an oral form 
(Fenton et al., 1999; White et al., 2003; Conte et al., 1995; Baici et al., 1992).  
                                                          
a 12% Horse Feed, Producers Cooperative, College Station, Texas 
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Horses were put into individual stalls to be fed.  They were allowed two hours to 
consume the meal, after which, any refusals were weighed back and discarded.  Horses 
had free access to water.  The chemical grade glucosamine-HCl used was obtained from 
Sigma Chemical Co., St. Louis, Missouri.  The chemical grade chondroitin-4-sulfate used 
was obtained from CarboMer, Inc., Westborough, Massachusetts.     
Sample Collection 
In each treatment period, horses were managed in dry-lot pens during a 14-day 
diet adaptation period with ad libitum access to water.  On day 15, blood samples were 
taken via indwelling jugular catheters.  The blood was drawn from the catheter and 
injected into heparinized tubes and immediately taken to the lab to be spun down and 
separated.  The plasma was then stored at -20°C until later analysis.  Blood samples were 
taken on one day during each period around the feeding at -30min, 30min, 60min, 90min, 
2 hr, 2.5hr, 3hr, 3.5hr, 4 hr, 4.5 hr, 5 hr, 5.5 hr, 6 hr, 7 hr, and 8 hr.  GAGs are cleared 
from the circulation within 4 hours (Revell and Muir, 1972). The absorption of GlucN 
has been proven to be relatively fast with a Tmax range of 1.1-1.6 h after oral treatments in 
dogs (Adebowale et al., 2002).   
Analytical Methods 
Chondroitin sulfate in the plasma was analyzed using a color reagent, 
dimethylmethylene blue (DMMB), followed by UV spectrophotometry (Baici et al., 
1992).  The DMMB assay for sulfated glycosaminoglycans (GAG) has found wide 
acceptance as a quick and simple method of measuring the sulfated GAG content of 
tissues and fluids (Farndale et al., 1986). Plasma samples were analyzed for glucosamine 
in the Laboratory for Protein Chemistry at Texas A&M University. 
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Chondroitin Sulfate Analyses 
Preparation of Plasma 
 After centrifugation of non-coagulated blood, plasma was retrieved and frozen at  
-20°C until analyses. One mL of plasma was mixed with 0.94 mL of 20mM sodium 
phosphate buffer and 60 uL of papain solution (10mg/mL) in the same buffer to eliminate 
proteins.  The sodium buffer contained 2mM EDTA and 2mM dithiothreitol at pH 6.8.  
The samples were incubated in a shaking water bath for 30 minutes at 45ºC, followed by 
30 minutes at 55ºC and finally at 120 minutes at 62ºC. Cloudy samples were incubated 
further to eliminate as much protein as possible.  After centrifugation for 30 minutes at 
3000g, the supernatants were analyzed the same day using UV spectrophotometry (Baici 
et al., 1992).  The assay was calibrated by use of blanks and standards containing 1 to 
5µg of the same CS as fed to the horses. 
Glycosaminoglycan assay 
To detect chondroitin sulfate in the plasma, a DMMB reagent was used; the same 
DMMB reagent as described above.  Two mL of the DMMB reagent was pipetted into a 
disposable polystyrene cuvette and was read at A525nm.  One hundred µL of sample was 
added and the sample was read again at A525nm 15s after mixing (Baici et al., 1992). 
Glucosamine Analysis 
 Plasma was obtained by centrifugation of non-coagulated blood and kept frozen at  
-20ºC until analysis.  Plasma was treated with acetonitrile to precipitate most of the 
proteins.  About 500 uL of the plasma/acetonitrile mixture were taken to the Texas A&M 
Protein Chemistry Lab for analyses. 
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Reagents 
 Glucosamine (GlucN) standards of 2ugm/mL to 1000ugm/mL GlucN, in water, 
were prepared.  Norvaline was used as the internal standard for the assay.  Free amino 
acid standards were obtained from Sigma Chemical Co. and Agilent, Palo Alto, 
California.   
Standard and Sample Preparation  
A duplicate set of standards between 2 and 8 ugm/mL GlucN were prepared for 
every assay.  Five nanomoles of 24 amino acids found in serum were added to 200uL of 
GlucN standard to further simulate the conditions found in the serum. Additionally five 
nanomoles of internal standard were added to all samples and standards. 
 Samples were then spun in a centrifuge to further remove any precipitate before 
analyses, and a 200uL aliquot was taken per sample. 
Method 
 All samples and standards were taken to dryness in a Savant Speed-Vac with 
radiant cover then reconstituted in 50uL of 0.4 M Borate buffer.  One microliter of re-
suspended sample was injected into the HPLC after automated pre-column derivitization 
with orthophthalaldehyde (OPA) in the presence of 3-mercaptopriopionic acid (3-MPA) 
to produce the isoindole derivative of the amino acids.  This derivative is detected at 338 
nm by an UV detector.  The amino acids and GlucN were separated on a Hypersil C-18 
column by gradient of a sodium acetate eluant.  Chromatographic conditions to be used 
were identical to those used for routine amino acid analysis in the Texas A & M  Protein 
Chemistry Lab except that the eluants contained a 3/4 strength Sodium Acetate 
concentration to allow separation in the middle of the chromatogram where Alanine, the 
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first anomer of GlucN and Arginine elute. (Eluant A: 14.5 mM sodium acetate, 0.05 mM 
EDTA with 180 uL TEA and 3 mLs THF per liter.  Eluant B: 14.5 mM sodium acetate, 
40% acetonitrile, 40% methanol, 20% water.)  Derivitized amino acids were separated on 
a Hypersyl AA from Agilent. 
To further confirm the accuracy of our GlucN analysis, spiked samples were 
analyzed.  Different methods were used to spike the plasma samples.  The first method 
included adding GlucN to the plasma before acetonitrile was added.  The second method 
included adding GlucN after the acetonitrile was added to the plasma and the proteins 
were precipitated and removed.  
 
Statistical Analyses 
All data were analyzed by analyses of variance appropriate for the Latin square 
design, using STATA statistical software, Stata Corp, 2001.  When necessary, means 
were further separated using a Fisher-Hayter means comparison test.  Differences were 
considered significant at P<0.05.   
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CHAPTER IV 
RESULTS AND DISCUSSION 
 
Glucosamine 
Calibration 
 
 Glucosamine elutes as a broad peak (Figure 1).  The first and last peaks represent 
the alpha and beta conformers and the area between these two peaks represents the linear 
form of the molecule.  While it is not possible to integrate the whole area under the curve 
due to the elution of arginine and taurine (Figure 2), it is possible to quantitate by either 
or both (simultaneously) of the anomeric peaks with linear results. In a blind study 
performed by the Texas A&M Protein and Chemistry Lab (PCL), spiked plasma samples 
were submitted for analysis in the range of 2 to 15 ugms/mL.  These samples were 
analyzed using both the alpha and beta peaks, averaging the results. Recovery of the 
GlucN in the spiked samples averaged at 98% (95-100%) (Figure 2).  This analysis 
resulted in very accurate results.  Quantitation threshold was determined to be 1 ugm/mL 
being 8 times the signal to noise ratio for these conditions. 
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Figure 1.   Elution of glucosamine 
 
 
 
 
Figure 2.  Chromatogram of horse plasma spiked with 10 µg/ml glucosamine-HCl 
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GlucN Results 
 In no case out of 250 samples was any glucosamine detected in the horse plasma 
(Figures 3-5). As shown in Figure 6, if glucosamine were present in the plasma samples, 
it would elute in two peaks.  Previous studies on absorption of GlucN have much higher 
reported values than the current study.  It is not clear whether the glucosamine molecule 
is absorbed in its entirety or is degraded prior to absorption (Brief et al., 2001).  In the 
current study, only whole glucosamine was analyzed for in the blood. Previously it has 
been shown that  GlucN from exogenous sources is incorporated into the metabolic 
pathway of GAG synthesis (Barclay et al., 1998).  After entering the cells, GlucN may be 
phosphorylated to give glucosamine-1-phosphate and subsequently N-acetylated, yielding 
acetylglucosamine-1-phosphate (GlucNAc-1-P).  N-acetylglucosamine is one of the 
intermediates in this GAG synthesis pathway.  These events could possibly account for 
the fact that no free GlucN was detected in the blood (Dr. Lennart Roden, personal 
communication, 2004). In an experiment in which D-glucosamine was given to rats via 
stomach tube, it appears likely that GlucN is phosphorylated, converted to fructose-6-
phosphate and metabolized (Kohn et al., 1962).  Also in previous studies, the 
bioavailability of GlucN has been studied in rats, dogs and man using radio-labeled 
GlucN (Setnikar et al., 1986; Tesiore, 1972). In a study performed by Setnikar et al, in 
1984, using labeled GlucN fed to rats, it was reported that the radioactivity found was not 
due to GlucN, but was from chemical entities, which changed over time. 
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Figure 3.  Chromatogram of plasma sample of horse 2C taken during period 1 at 
                  hour 4 
 
 
 
 
 
Figure 4.  Chromatogram of plasma sample of horse 2C taken during period 2 at  
                 hour 4 
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      Minutes 
Figure 5.  Chromatogram of plasma sample of horse 2C taken during period 3 at 
                   hour 4 
                                                                                                                               
 
 
 
Figure 6.  Sample of horse plasma overlayed with 10 µg/ml standard 
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Chondroitin Sulfate  
Diet and Period Effects 
 
 There were no significant differences between treatments in  the amount of CS 
found in the blood based on diet (Table 1).  There was, however, a significant (P<0.05) 
period effect.  Mean plasma concentrations of CS were significantly lower in period 3 
than in the other periods (Table 2). Chondroitin sulfate concentrations were lower for all 
three diets during period 3 (Table 3).  In order to further examine period effects, an 
ANOVA was done to examine any effects of the sequence in which horses received the 
treatments (Appendix 2).  There was no noted sequence effect (P<0.05) indicating that 
the lower plasma concentrations of CS in period 3 were not due to adaptation.  
 
Table 1.  Mean Plasma Concentrations of Chondroitin Sulfate by Diet Over All 
Periods 
Mean (mg/mL) SE
Control 62.4 6.7
Level 1Diet 79.9 7.4
Level 2 Diet 75.1 7.3
Total 72.2 4.1
Chondroitin Sulfate
 
 
 
 
Table 2.  Mean Plasma Concentrations of Chondroitin Sulfate by Period Over All 
Treatments 
Mean (mg/mL) SE
Period 1 81.5 7.4
Period 2 87.8 6.3
Period 3 48.4* 6.5
Total 72.2 4.1
Chondrotin Sulfate
 
*Period 3 significantly different from other periods (P<0.05) 
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Table 3.  Mean Plasma Concentrations of Chondroitin Sulfate by Diet and Period 
M e a n  (m g /m L ) S E
P e r io d  1
D ie t  1 8 8 .5 1 5 .3
D ie t  2 8 7 .3 1 0 .9
D ie t  3 6 5 .8 1 1 .7
T o ta l 8 1 .5 7 .4
P e r io d  2
D ie t  1 6 8 .9 8 .3
D ie t  2 9 9 .6 1 4 .4
D ie t  3 9 6 .8 9 .1
T o ta l 8 7 .8 6 .3
P e r io d  3
D ie t  1 3 7 .1 9 .4
D ie t  2 5 5 .6 1 0 .3
D ie t  3 5 3 .8 1 4 .4
T o ta l 4 8 .4 6 .5
C h o n d r o i t in  S u lfa te
 
 
Time Effects 
To better visualize and further examine the change in chondroitin sulfate over 
time, the data points were normalized to baseline values.  When the blood samples were 
taken following feeding, there was no noted significant (P<0.05) change in the blood 
concentration due to feeding CS (Appendix 3).  Never at any point was there a significant 
increase in plasma CS levels over the baseline value during the eight hour sampling 
period post-feeding (Figure 7).   
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  Figure 7.  Postprandial curve – CS levels in plasma around feeding 
 
 
Figure 7 illustrates that there was no significant postprandial response to feeding 
CS in diets 2 and 3.  If chondroitin sulfate was present in the plasma after being fed, there 
should have been an increase in concentration of CS when horses were fed diets 2 and 3 
compared to diet 1.  The results obtained here seem logical when looking at the chemical 
make-up of chondroitin sulfate.  Mass of CS can range from 14,000 Da to 30,000 Da.  Its 
weight would suggest that absorption across the gastrointestinal mucosa, which contains 
a variety of GAG-degrading enzymes, is low (Eddington and White, 2001).  
 In the current study, there was no effect on plasma CS concentrations due to 
orally administering CS to horses. Previous studies have used radiolabeled chondroitin 
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sulfate and absorption results were based on recovery of radioactivity.  Conte et al. 
(1995) reported over 70% absorption of label from CS when fed to rats and dogs.  Total 
radioactivity in that study was based on the sum of exogenous chondroitin sulfate and of 
several labeled molecular species which derive from its depolymerization and catabolism 
(Conte et al., 1995).   This study and one performed by Palmieri et al. (1990) used a 
labeling method that produces a chondroitin sulfate molecule with a single label at the 
reducing end of the molecule.  This sort of labeling is not representative of the whole 
molecule, and measuring the radioactivity of any absorbed material actually means 
following the metabolic fate of the very last residue in the polymer backbone (Baici et al., 
1992).  
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CHAPTER V 
 
GENERAL DISCUSSION 
 
 With degenerative joint disease (DJD) and osteoarthritis posing such a major  
problem in the equine industry today, many different treatments, such as administering 
glucosamine (GlucN) and chondroitin sulfate (CS), have been designed to reduce pain 
and inflammation along with improving joint function. GlucN and CS are endogenous 
molecules to the equine system and are essential for proper cartilage formation and joint 
function (Brief et al., 2001).  To fully elucidate the effects of oral forms of these products 
on joint health in animals such as horses, more information must first be known about 
their bioavailability.   
Glucosamine 
The pharmacokinetics of GlucN are difficult to investigate because it is an 
endogenous substance which is rapidly utilized by the body for the biosynthesis of other 
normal constituents (Adebowale et al., 2002).  The majority of the previous studies 
conducted on animals involved feeding uniformly labeled GlucN.  The use of 
radiolabeled GlucN to determine total radioactivity in biological fluids fails to detect 
presystemic metabolism in the gut or liver during absorption since drug and metabolites 
are not differentiated (Adebowale et al., 2002).  In a previous study, it was stated that 
indirect evidence was available to support the fact that GlucN may be degraded by 
intestinal flora.  It was also noted that their results did not exclude the possibility that 
some GlucN was converted to a readily absorbed degradation product (Capps et al., 
1966).  According to Setnikar et al. (1984) more than 81% of the administered 
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radioactivity was recovered in CO2.  This shows the high degree of metabolism of 14C 
GlucN after oral administration (Setnikar et al., 1984). It has also been stated that 
glucosamine absorbed by the gastrointestinal tract undergoes significant first-pass 
metabolism in the liver (Barclay et al., 1998).  As a result of hepatic metabolism, GlucN 
may be incorporated into plasma proteins (Setnikar et al., 1986; Setnikar et al., 1993).  
This along with the fact that systemic availability is always overestimated when 
radioactivity is used may explain the difference found between the amount of GlucN 
absorbed in this study compared to previous studies. 
Chondroitin Sulfate 
 The actual metabolic uptake of orally administered chondroitin sulfate has been 
found to be inconsistent, possibly because of variation in the structure, biochemical 
properties, and molecular weights of the various preparations (Brief et al., 2001). 
According to Dohlman, (1956) CS is degraded in the gastrointestinal tract and no intact 
CS can be absorbed through the intestinal wall.  It is known that when given 
intravenously, CS is degraded mainly if not solely by the liver.  The sulfate groups are 
lost as inorganic sulfate (Baici et al., 1992; Wood et al., 1973; Revell and Muir, 1972).  
The question that remains is whether CS makes it out of the gut to the liver to be 
degraded.  One study was conducted to investigate the impact of oral chondroitin sulfate 
on the concentration of glycosaminoglycans in human serum. It was found that CS was 
not absorbed either in an intact form or as a sulfated oligosaccharide and therefore, did 
not produce any measurable change in the total serum concentration of 
glycosaminoglycans (Baici et al., 1992).  The authors of this study concluded that the 
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theory that orally administered CS alone offers chondroprotection is biologically and 
pharmacologically unfounded (Brief et al., 2002).     
 To offer an explanation of why the present study did not reveal a postprandial 
curve when measuring whole CS after it was fed orally, first it is important to understand 
the metabolism of CS as it travels through the gastrointestinal tract (Lualdi, 1993). In its 
native form in the cartilage, CS is part of a huge proteoglycan core protein with up to 100 
chondroitin sulfate chains attached.  Many of these macromolecules are bound 
noncovalently to hyaluronan to yield complexes with a mass of up to 200 million daltons 
(Dr. Lennart Roden, personal communication, 2004). The intestinal epithelium is a highly 
effective barrier, which hinders the diffusion of a wide variety of high molecular mass 
compounds, such as CS. It has been shown that in humans, CS is not absorbed in the 
intestine, but the bacteria of the large intestine utilize CS as an energy source (Salyers, 
1979).  These microorganisms metabolize CS by the action of three enzymes.  First, a 
periplasmatic CS-lyase releases unsaturated disaccharides from the CS polymer.  Next, 
the disaccharide is desulfated by an intracellular sulfatase, and finally an intracellular 
glucuronidase splits the disaccharide into monomers.  The monomers are then used as an 
energy source and no evidence has been found for the production of CS fragments larger 
than the disaccharide (Salyers and O’Brien, 1980).  This information offers enough 
evidence to assert that neither intact, nor depolymerized CS is absorbed by the 
mammalian gastrointestinal tract (Lualdi, 1993).  
The possibility that low molecular mass desulfated oligomers and monomers may 
be produced from the breakdown of CS cannot be ruled out on the basis of this sudy.  
Without the existence of a polymer chain and the presence of sulfate groups, CS would 
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not retain the biochemical and biological properties attributed to the intact molecule 
(Baici et al., 1992).  Because all of the claims regarding pharmacological effects of CS 
refer to the properties of this molecule as a whole molecule, not to the properties of any 
degradation product, any direct action of orally administered CS on cartilage and 
chondrocytes is not possible (Lualdi, 1993).  
Many unanswered questions remain surrounding the most effective dosage and 
route along with any actual beneficial effects of glucosamine and chondroitin sulfate.  
GlucN and CS, when administered in a pure bioavailable form, have been show to be safe 
(Adebowale et al., 2000).  When fed to rats at the high level of 5g/kg body weight, they 
proved to be non-toxic (Davidson, 2000).  A well-designed prospective study of the 
metabolism of these products as they travel through the gastrointestinal tract of the 
equine needs to be conducted. 
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CHAPTER VI 
 
SUMMARY AND CONCLUSIONS 
  
 
 Many compounds are commercially available which claim to “improve joint 
health”.  This study was conducted to further elucidate unanswered questions surrounding 
“nutraceuticals”, specifically glucosamine and chondroitin sulfate.  Six mature horses 
were fed diets with pure GlucN and CS top dressed on their feed.  Blood samples were 
taken and appropriate analyses were run to determine if either whole GlucN or whole CS 
was present or increased in the blood due to oral dosing.   
When feeding pure GlucN to mature horses at two different amounts, there was 
no detectable GlucN measured in the plasma.  These data are obviously different than 
previous reports, but a lot of questions about the exact fate of exogenous GlucN in the 
equine gastrointestinal tract remain to be answered.   
 Chondroitin sulfate is a molecule known to be endogenous to horses.  When 
horses were fed an exogenous source of CS, plasma samples contained no significant 
increase in amounts of CS to produce a postprandial curve.  It is well documented in the 
literature that the mammalian gastrointestinal tract is not suited for allowing whole CS to 
be absorbed.   
 Due to the lack of significant amounts of either GlucN or CS in the blood, this 
study does not support the theory that orally dosed GlucN and CS are readily available to 
the joints through the bloodstream.  With the enormous impact that “nutraceuticals” are 
having on the equine industry, it is important to know whether resources are being used 
efficiently and effectively.  The ability to lessen the effects of DJD and osteoarthritis are 
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important.  However, more research is needed to determine if oral products containing 
glucosamine and chondroitin sulfate are actually efficacious in that regard.  
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APPENDIX 
1.  ANOVA Table for Chondroitin Sulfate in the Blood – Overall Diet and Period 
Effects 
Source df Partial SS MS F-value P-value
Total 132 297754.3290 2255.7146
Model 8 59019.9151 7377.4894 3.8300 0.0005
Error 124 238734.4140 1925.2775
Diet 2 5711.9961 2855.9981 1.4800 0.2309
Period 2 41259.2987 20629.6494 10.7200 0.0000
Diet*Period 4 9362.6296 2340.6574 1.2200 0.3075
 
 
2.  ANOVA Table for Chondroitin Sulfate in the Blood- Overall Diet, Period and 
Time Effects 
Source df Partial SS MS F-value P-value
Total 132 297754.3290 2255.7146
Model 32 123120.3710 3847.5116 2.2000 0.0016
Error 100 174633.9580 1746.3396
Diet 2 5761.2211 2880.6105 1.6500 0.1973
Period 2 40866.2953 20433.1477 11.7000 0.0000
Time 8 21532.4499 2691.5562 1.5400 0.1526
Diet*Time 16 41587.4186 2599.2137 1.4900 0.1189
Diet*Period 4 11104.2289 2776.0572 1.5900 0.1829
 
 
 
 
3.  ANOVA Table for Crossover Effects 
Source of Variation df Partial SS MS F-value P-value
Intersubjects
     Sequence effect 2 46.37 23.19 0.9500 0.4778
Error 3 72.89 24.30 1.2700 0.2880
Intrasubjects
      Treatment effect 2 76.55 38.27 2.0000 0.1398
           Period effect 2 431.78 215.89 11.2800 0.0000
    Error 123 2354.44 19.14
Total 132 2977.54
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4. ANOVA Table for CS concentrations in the blood – time effects by diet 
 
Diet 1
Source df Partial SS MS F-value P-value
Total 46 95956.6194 2086.0135
Model 8 16490.1602 2061.2700 0.9900 0.4622
Error 38 79466.4591 2091.2226
Diet 2 16490.1602 2061.2700 0.9900 0.4622
Diet 2
Source df Partial SS MS F-value P-value
Total 43 103609.188 2409.516
Model 8 24270.9159 3033.8645 1.34 0.2576
Error 35 79338.2722 2266.8078
Diet 8 24270.9159 3033.8645 1.34 0.2576
Diet 3
Source df Partial SS MS F-value P-value
Total 41 90678.1942 2211.6633
Model 8 22416.9016 2802.1127 1.35 0.2524
Error 33 68261.2929 2068.524
Diet 8 22416.9013 2802.1127 1.35 0.2524  
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5.  Normalized Mean Table Separated by Diet and Time 
 
Diet 1
Time Mean SE
0 0.0000 0.0000
1 -13.0950 25.5474
2 7.5092 34.3538
4 2.2387 29.2316
4 21.3342 18.0408
5 68.6460 17.4979
6 52.4348 20.9948
7 18.6467 14.0895
8 29.1475 18.9774
Total 18.848 8.0475
Diet 2
Time Mean SE
0 0.0000 0.0000
1 -45.1250 18.1041
2 1.3060 38.1927
4 0.0837 39.2345
4 47.8600 13.1286
5 -6.3050 27.7502
6 -0.2413 34.2838
7 5.6500 22.0500
8 -46.2567 25.3972
Total -3.6689 9.2311
Diet 3
Time Mean SE
0 0.0000 0.0000
1 26.8.5 58.3850
2 -46.6875 44.5575
4 4.3750 55.1950
4 -20.1375 69.0675
5 -50.5975 70.7875
6 -30.5225 71.5025
7 -49.6800 15.1800
8 14.2250 53.5550
Total -16.9133 14.7625  
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